Ignite Creation Date:
2025-12-25 @ 4:50 AM
Ignite Modification Date:
2026-02-26 @ 12:03 PM
Study NCT ID:
NCT01847118
Status:
UNKNOWN
Last Update Posted:
2015-03-24
First Post:
2013-04-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors
Sponsor:
Jiangsu Simcere Pharmaceutical Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
SIM-63-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None